269 related articles for article (PubMed ID: 18756940)
41. Zoledronic acid: a new parenteral bisphosphonate.
Li EC; Davis LE
Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
[TBL] [Abstract][Full Text] [Related]
42. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
[TBL] [Abstract][Full Text] [Related]
43. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
44. Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.
Gui Q; Xu C; Li D; Zhuang L; Xia S; Yu S
Mol Med Rep; 2015 Sep; 12(3):4243-4249. PubMed ID: 26081451
[TBL] [Abstract][Full Text] [Related]
45. [Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer].
Cheng J; Xue J; Wu HG; Wu G
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):552-4. PubMed ID: 19062728
[TBL] [Abstract][Full Text] [Related]
46. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
Cha YJ; Lee YJ
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):274-82. PubMed ID: 23357846
[TBL] [Abstract][Full Text] [Related]
47. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
[TBL] [Abstract][Full Text] [Related]
48. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
49. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Reed SD; Radeva JI; Glendenning GA; Coleman RE; Schulman KA
Am J Clin Oncol; 2005 Feb; 28(1):8-16. PubMed ID: 15685028
[TBL] [Abstract][Full Text] [Related]
50. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF
In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922
[TBL] [Abstract][Full Text] [Related]
51. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
Terpos E; Berenson J; Cook RJ; Lipton A; Coleman RE
Leukemia; 2010 May; 24(5):1043-9. PubMed ID: 20376081
[TBL] [Abstract][Full Text] [Related]
52. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
53. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
Lacerna L; Hohneker J
Semin Oncol; 2003 Oct; 30(5 Suppl 16):150-60. PubMed ID: 14613036
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Amadori D; Aglietta M; Alessi B; Gianni L; Ibrahim T; Farina G; Gaion F; Bertoldo F; Santini D; Rondena R; Bogani P; Ripamonti CI
Lancet Oncol; 2013 Jun; 14(7):663-70. PubMed ID: 23684411
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Coleman RE
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
[TBL] [Abstract][Full Text] [Related]
56. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
[TBL] [Abstract][Full Text] [Related]
57. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
58. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
59. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
60. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
